

Prior Authorization Review Panel

CHC-MCO Policy Submission

A separate copy of this form must accompany each policy submitted for review. Policies submitted without this form will not be considered for review.

Plan: PA Health & Wellness	Submission Date: 08/01/2022	
Policy Number: PHW.PDL.040	Effective Date: 01/01/2020 Revision Date: 07/2022	
Policy Name: Smoking Cessation Products	•	
Type of Submission – <u>Check all that apply</u> :		
□ New Policy□ Revised Policy*		
 ✓ Annual Review - No Revisions ✓ Statewide PDL - Select this box when submitting policies j when submitting policies for drug classes included on the S 		
*All revisions to the policy <u>must</u> be highlighted using track changes throughout the document.		
Please provide any changes or clarifying information for the policy below:		
Updated wording per DHS		
Name of Authorized Individual (Please type or print):	Signature of Authorized Individual:	
Venkateswara R. Davuluri, MD	C-Raulun	
	.,	

CLINICAL POLICY

Smoking Cessation Products



Clinical Policy: Smoking Cessation Products

Reference Number: PHW.PDL.040

Effective Date: 01/01/2020 Last Review Date: 07/2022

Revision Log

Policy/Criteria

Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

It is the policy of PA Health & Wellness® that Smoking Cessation Products are **medically necessary** when the following criteria are met:

I. Requirements for Prior Authorization of Smoking Cessation Products

A. Prescriptions That Require Prior Authorization

Prescriptions for Smoking Cessation Products that meet the following conditions must be prior authorized.

- 1. A prescription for a non-preferred Smoking Cessation Product regardless of the quantity prescribed.
- 2. A prescription for a preferred Smoking Cessation Product with a prescribed quantity that exceeds the quantity limit.

B. Review of Documentation for Medical Necessity

In evaluating a request for prior authorization of a prescription for a non-preferred Smoking Cessation Products, the determination of whether the requested prescription is medically necessary will take into account whether the recipient:

For a non-preferred Smoking Cessation product, has a history of therapeutic failure of or a contraindication or an intolerance to the preferred Smoking Cessation Products; **AND**

1. If a prescription for a Smoking Cessation Product is in a quantity that exceeds the quantity limit, the determination of whether the prescription is medically necessary will also take into account the guidelines set forth in PA.CP.PMN.59 Quantity Limit Override.

NOTE: If the beneficiary does not meet the clinical review guidelines listed above but, in the professional judgment of the physician reviewer, the services are medically necessary to meet the medical needs of the beneficiary, the request for prior authorization will be approved.

C. Clinical Review Process

CLINICAL POLICYSmoking Cessation Products



Prior authorization personnel will review the request for prior authorization and apply the clinical guidelines in Section B. above, to assess the medical necessity of the request for a prescription for a non-preferred Smoking Cessation Product. If the guidelines in Section B are met, the reviewer will prior authorize the prescription. If the guidelines are not met, the prior authorization request will be referred to a physician reviewer for a medical necessity determination. Such a request for prior authorization will be approved when, in the professional judgment of the physician reviewer, the services are medically necessary to meet the medical needs of the recipient.

D. Approval Duration: 12 months

Reviews, Revisions, and Approvals	Date
Policy created	01/01/2020
Q1 2021 annual review: no changes.	01/2021
Updated wording per DHS	07/2022